| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.39 | 8e-29 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.21 | 4e-10 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-09 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-07 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-06 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.19 | 4e-05 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.2 | 0.0002 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0002 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0002 |